共查询到18条相似文献,搜索用时 171 毫秒
1.
2.
肿瘤多药耐药是肿瘤治疗过程中一个亟待解决的难题,其表现为肿瘤细胞对单一或多种化疗药物同时出现耐药性,从而导致治疗失败,与药物的化学结构和作用机制无关。将化疗药物与肿瘤多药耐药逆转剂联合应用是目前公认的治疗方案之一。黄酮类化合物由于其低毒、高效,具有多种药理作用等优点而受到广泛的关注。在肿瘤治疗期间,黄酮类化合物能通过抑制ABC转运体、诱导凋亡、调节氧化应激等作用逆转肿瘤多药耐药。归纳总结了黄酮类化合物逆转肿瘤多药耐药的主要机制、应用及其纳米剂型改造的进展,为进一步的临床研究提供参考。 相似文献
3.
4.
肿瘤多药耐药(multidrug resistance,MDR)是临床上导致化疗失败的重要原因。采用化疗药物与多药耐药逆转剂联合给药是逆转多药耐药的非常具有前景的策略。目前黄酮类化合物在逆转多药耐药上显示出较大潜力。黄酮类化合物可以通过抑制外排蛋白、诱导凋亡、调节细胞周期以及调节细胞内氧化应激等发挥逆转耐药的作用。黄酮类化合物可以单独给药或与化疗药物等联合给药用于逆转肿瘤多药耐药。本文就黄酮类化合物逆转MDR的机制及应用研究进展进行综述。 相似文献
5.
6.
7.
近年来,关于多药耐药性的研究越来越多,而关于多药耐药基因的研究已成为目前化疗药物耐药机制研究的重要方面,多药耐药基因、P-糖蛋白介导的卵巢癌耐药是当前研究的热点,近些年已开展了一系列关于激素类基因与卵巢癌耐药关系的实验研究。本文综述了激素类基因与卵巢癌耐药关系的研究进展。 相似文献
8.
卵巢癌是妇科恶性肿瘤之一,死亡率高,愈后差,如果治疗方法得当,不仅可以延长生命,而且可以达到治愈效果。卵巢癌以手术治疗为主,配合化疗是治疗的主要辅助手段,术后化疗配合护理至关重要,即使广泛转移也能取得一定的疗效。铂化合物被广泛应用于妇科肿瘤的化疗,并... 相似文献
9.
10.
11.
12.
真菌耐药的现状与对策 总被引:7,自引:0,他引:7
真菌耐药的报道日益增多,目前的研究一方面进一步探讨真菌产生耐药的机制、传播方式、耐药性与临床治疗的关系,以及建立标准化抗真菌药物敏感试验,从而控制耐药性的进一步发展;另一方面加快开发新的抗真菌药物,以应对日益增多的耐药真菌。 相似文献
13.
《Expert opinion on therapeutic targets》2013,17(7):817-828
Introduction: Pancreatic cancer has the worst survival rate of all cancers. The current standard care for metastatic pancreatic cancer is gemcitabine, however, the success of this treatment is poor and overall survival has not improved for decades. Drug resistance (both intrinsic and acquired) is thought to be a major reason for the limited benefit of most pancreatic cancer therapies. Areas covered: Previous studies have indicated various mechanisms of drug resistance in pancreatic cancer, including changes in individual genes or signaling pathways, the influence of the tumor microenvironment, and the presence of highly resistant stem cells. This review summarizes recent advances in the mechanisms of drug resistance in pancreatic cancer and potential strategies to overcome this. Expert opinion: Increasing drug delivery efficiency and decreasing drug resistance is the current aim in pancreatic cancer treatment, and will also benefit the treatment of other cancers. Understanding the molecular and cellular basis of drug resistance in pancreatic cancer will lead to the development of novel therapeutic strategies with the potential to sensitize pancreatic cancer to chemotherapy, and to increase the efficacy of current treatments in a wide variety of human cancers. 相似文献
14.
15.
肺癌是癌症相关死亡的首要原因。非小细胞肺癌(NSCLC)约占肺癌的85%,且患者在诊断时大多为晚期。随着表皮生长因子受体(EGFR)在肺癌中被发现,针对特定基因突变的靶向治疗成为晚期NSCLC的重要治疗方式,并显著延长了患者生存期。尽管第一、二、三代EGFR-酪氨酸激酶抑制剂(TKI)蓬勃发展,但随着治疗时间的推移,患者都可能面临耐药和进展。为克服这一难题,基于耐药机制的相关治疗策略正在研究中。本文旨在对近年来EGFR-TKIs,特别是在疗效及安全性上作为指南更优推荐的第三代EGFR-TKIs的耐药机制和治疗策略的研究进展进行综述。 相似文献
16.
《Expert opinion on therapeutic targets》2013,17(5):561-580
ATP-binding cassette (ABC) transporters have been the subject of intense scrutiny as potential mediators of clinical drug resistance. Since the identification of MDR1/P-glycoprotein over 15 years ago, it has been recognised that reduced intracellular accumulation of anticancer agents can result in significant degrees of drug resistance. The multi-drug resistance associated protein (MRP1) was the second ABC transporter to be associated with drug resistance, and in the past three years, five additional MRP family members have been recognised. While studies to define the substrate specificity and normal physiology for the new transporters is underway, it appears that the principal function for P-glycoprotein and MRP is protection of the host from xenobiotics. The most recent addition to the list of ABC transporters mediating drug resistance is the half-transporter, MXR/BCRP/ABCP. Overexpression of this transporter is associated with mitoxantrone, anthracycline and camptothecin resistance. The discovery of multiple distinct ABC transporters capable of conferring multi-drug resistance offers the possibility that clinical reversal of drug resistance can be achieved. Studies with P-glycoprotein inhibitors alone have generated mixed results; one potential explanation is that other transporters may be co-expressed. These additional transporters offer new therapeutic targets, as both specific and multi-specific inhibitors should be identified for clinical trials in drug resistance reversal. 相似文献
17.
Mehri Niazi Parvin Zakeri-Milani Saeedeh Najafi Hajivar Mehdi Soleymani Goloujeh Nasrin Ghobakhlou Javid Shahbazi Mojarrad 《Expert opinion on drug metabolism & toxicology》2016,12(9):1021-1033
Introduction: The discussion about cancer treatment has a long history. Chemotherapy, one of the promising approaches in cancer therapy, is limited in the clinic as plenty of factors evolve and prevent appropriate therapeutic response to drugs. Multi-drug resistance (MDR), which is mostly P-glycoprotein-mediated, is described as the most well-known impediment in this contribution. It extrudes several agents out of cells, arising MDR and decreasing the bioavailability of drugs. Hence, cancer cells become insensitive to chemotherapy.Areas covered: Many agents have been developed to reverse MDR, but it is difficult to deliver them into cancer sites and cancer cells. The emerging nano-based drug delivery systems have been more effective to overcome P-glycoprotein-mediated MDR by increasing the intracellular delivery of these agents. Here, we represent systems including siRNA-targeted inhibition of P-gp, monoclonal antibodies, natural extracts, conventional inhibitors, hard nanoparticles and soft nanoparticles as delivery systems in addition to a novel approach applying cell penetrating peptides.Expert opinion: Overcoming cancer drug resistance using innovative nanotechnology is being increasingly used and developed. Among resistance mechanisms, drug efflux transporter inhibitors and MDR gene expression silencing are among the those being investigated. In the near future, it seems some of these nanomedical approaches might become the mainstay of effective treatment of important human conditions like cancer. 相似文献
18.
肿瘤是威胁人类生存与健康的重要原因之一。在肿瘤的药物治疗中,化疗是常用手段之一,但由于其特异性低、不良反应大、长期使用易产生耐药性等问题,应用受到较大限制。基于DNA损伤修复机制开发的新型抗肿瘤药物聚腺苷酸二磷酸核糖聚合酶(poly-ADP ribose polymerase,PARP)抑制剂可能是解决这一问题的关键。PARP抑制剂是一类靶向抑制PARP-1蛋白,诱导BRCA基因突变的肿瘤细胞发生“合成致死”现象的新型抗肿瘤药物,已成功应用于卵巢癌、乳腺癌等肿瘤的治疗。近年来PARP抑制剂更是与各类一线化疗药、靶向制剂及免疫检查点抑制剂等进行联合治疗,扩大了临床适用范围。本文将对PARP抑制剂的药理作用与作用机制、在肿瘤治疗中的应用及其耐药机制等研究进展进行总结,以期为PARP抑制剂的临床应用提供合理指导。 相似文献